Physician

Christopher Mark Mathews, M.D.

According to 2025 Medicare claims, Christopher Mathews, M.D. (NPI: 1134166291) practices gastroenterology in the Kingsport-Bristol, TN-VA market, with the plurality of this provider's patient population coming from Sullivan, TN. This provider's primary affiliated billing organization is GASTROENTEROLOGY ASSOCIATES (NPI: 1770578270; TIN: 621348249) and primary practice location at 37660-3809. Mathews is affiliated with the AnewCare Collaborative, LLC (ACO ID: A1241) and Emergent ACO 24.1, LLC (ACO ID: A5378), participating under the MSSP model.

Mathews' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 506 traditional Medicare patients, billed 3,850 HCPCS/CPT codes, and received $206,533 in Medicare payments. The top billing code was 45385 (Removal of polyps or growths of large bowel using an endoscope with mechanical snare). Part D data shows 1,676 prescription claims across 650 beneficiaries totaling $1,224,427 in drug costs, led by Stelara (Ustekinumab). 2017 DME data shows 24 claims. Open Payments data shows 62 records totaling $929. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $115,210 to $206,533. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $376,060 and ending at $1,224,427. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	432	1,383	$115,210
2016	463	1,510	$126,894
2017	459	1,509	$119,060
2018	424	1,382	$112,587
2019	442	1,450	$118,196
2020	362	1,360	$90,773
2021	421	2,622	$138,213
2022	421	3,058	$163,600
2023	442	3,288	$169,248
2024	506	3,850	$206,533

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	599	2,119	$376,060
2016	627	2,068	$781,166
2017	551	1,663	$506,025
2018	537	1,615	$388,885
2019	478	1,376	$269,586
2020	488	1,420	$262,699
2021	488	1,412	$417,033
2022	488	1,427	$278,254
2023	490	1,521	$1,196,434
2024	650	1,676	$1,224,427

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	24	$831
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
45385	Removal of polyps or growths of large bowel using an endoscope with mechanical snare	135	138	$196
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	197	262	$82
99490	Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month	116	770	$45
99439	Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month	111	1,388	$35
88305	Pathology examination of tissue using a microscope, intermediate complexity	202	378	$23

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Stelara	Ustekinumab	20	938	$552,873
Humira(Cf) Pen	Adalimumab	21	588	$345,354
Linzess	Linaclotide	29	1,290	$22,666
Ibsrela	Tenapanor Hcl	16	480	$19,534
Sod Sulf-Potass Sulf-Mag Sulf	Sodium, Potassium,mag Sulfates	200	277	$12,567

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	62	$929	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christopher Mark Mathews, M.D.?

Tedicare shows public-source Medicare data for Christopher Mark Mathews, M.D. (NPI 1134166291), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christopher Mark Mathews, M.D. have ACO affiliation data?

Christopher Mark Mathews, M.D. is shown with ACO affiliation data for AnewCare Collaborative, LLC (MSSP, ACO ID A1241) and Emergent ACO 24.1, LLC (MSSP, ACO ID A5378).

What billing organization is linked to Christopher Mark Mathews, M.D.?

Christopher Mark Mathews, M.D. is linked to GASTROENTEROLOGY ASSOCIATES (billing NPI 1770578270) in the available physician profile data.

Does Christopher Mark Mathews, M.D. have Open Payments data?

Christopher Mark Mathews, M.D. has 62 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.